Paola Modaffari

Dr. Paola Modaffari

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Clinical Breast Cancer
Verified
Journal Article
Closed access
MDMarta D'ALonzo
Marta D'ALonzo
EPEleonora Piva
Eleonora Piva
SPSilvia Pecchio
Silvia Pecchio
VLViola Liberale
Viola Liberale
PMPaola Modaffari
Paola Modaffari
NBNicoletta Biglia
Nicoletta Biglia

29 April 2016 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
NBNicolas Bourdel
Nicolas Bourdel
PMPaola Modaffari
Paola Modaffari
ETEnrica Tognazza
Enrica Tognazza
RPRiccardo Pertile
Riccardo Pertile
PCPauline Chauvet
Pauline Chauvet
MCmichel jean Canis
michel jean Canis

31 May 2012 in Gynecologic and Obstetric Investigation
Verified
Journal Article
Closed access
EPE. Piovano
E. Piovano
EPE. Pivetta
E. Pivetta
PMPaola Modaffari
Paola Modaffari
FMF. Martra
F. Martra
CPC. Baima Poma
C. Baima Poma
AFAnnamaria Ferrero
Annamaria Ferrero
Aims: To investigate the frequency of and predictive factors for hypersensitivity reactions (HR) to taxanes and platinum salts in a cohort of patients treated for pelvic gynecologic malignancies. Methods: The medical records of all patients with gynecologic pelvic neoplasms treated with chemotherapy at the Department of Gynecologic Oncology, AO Mauriziano Umberto I of Turin, from September 2007 through August 2008, were retrospectively reviewed. Two multivariate models, regarding carboplatin and taxane chemotherapy, respectively, were performed to evaluate the potential predictive value of various clinical features. Results: The incidence of HR was 14% (22/157). Multivariate models showed that menopausal women had a significantly lower probability of HR (OR 0.12, CI 0.02–1.13, p = 0.06 for the carboplatin model and OR 0.05, CI 0.01–0.63, p = 0.02 for the taxane model) while a history of systemic hypersensitivity was associated with a higher but non-significant risk of HR (OR 2.64, CI 0.78–8.95, p = 0.11, for the carboplatin model and OR 3.42, CI 0.94–12.45, p = 0.06, for the taxane model). Conclusion: We confirmed a history of hypersensitivity as a risk factor for HR. Other larger cohorts should be analyzed: we need to find new predictive factors in order to select women who should be submitted to experimental prophylactic strategies.

Verified
Journal Article
Open access
PDF file
PMPaola Modaffari
Paola Modaffari
Riccardo PonzoneRiccardo Ponzone
Riccardo Ponzone
AFAlberta Ferrari
Alberta Ferrari
ICIsabella Cipullo
Isabella Cipullo
VLViola Liberale
Viola Liberale
NBNicoletta Biglia
Nicoletta Biglia
Hereditary Breast and Ovarian Cancer syndrome (HBOC) carriers face complex decisions, which might affect their fertility and body image. Using an anonymous 40-items questionnaire we evaluated the expectations and concerns about Risk-Reducing Surgery (RRS) in 204 carriers. Participants are well-informed about the options to manage cancer risk, and women with previous cancer are more concerned with screening failure. Satisfaction with RR Mastectomy is high, even if many carriers are unsatisfied with reconstructed breast feel and nipple-areola complex tactile sensation and those with previous breast cancer report a change in their sexual habits. The decrease of libido and vaginal dryness are the most complained symptoms after RR Salpingo-Oophorectomy. Nevertheless, most carriers would choose RRS again, due to cancer risk or screening-related stress reduction. Women who deferred RRS are more afraid of menopausal symptoms and cancer risk than those who had undergone or declined surgery. Women who declined RRS feel well-informed and trust screening procedures. In conclusion, HBOC carriers consider themselves well-informed and able to choose the best option for their condition, would choose RRS again because of cancer risk and screening-related stress reduction, and those who delay RRS face a higher preoperative level of concern and need support.

1 December 2011 in Gynecologic Oncology Case Reports
Verified
Journal Article
Open access
EPElisa Piovano
Elisa Piovano
AFAnnamaria Ferrero
Annamaria Ferrero
NRNicoletta Ravarino
Nicoletta Ravarino
FMF. Martra
F. Martra
PMPaola Modaffari
Paola Modaffari
PZPaolo Zola
Paolo Zola
► Syringoid eccrine carcinoma (SEC) is a rare tumor. ► There are no published reports describing diagnosis of this tumor on the vulva. ► We report a case of a 58-year-old female with a SEC of left labia majora.

21 September 2017 in Gynecological Endocrinology
Verified
Journal Article
Closed access
PMPaola Modaffari
Paola Modaffari
MDMarta D’aLonzo
Marta D’aLonzo
MGMarta Garbagnati
Marta Garbagnati
SPSilvia Pecchio
Silvia Pecchio
GMGuido Menato
Guido Menato
NBNicoletta Biglia
Nicoletta Biglia
Ulipristal acetate (UPA) has been recognized as an alternative strategy to surgery in the management of symptomatic women with uterine fibroids. We present a case report on a woman with hereditary fibrinogen deficiency exclusively treated with UPA for myoma-related menorrhagia and abdominal pain, who subsequently underwent a hysterectomy because of clinical worsening. A FIGO IB uterine leiomyosarcoma was found among multiple myomas. A review of the literature found two other cases of uterine leiomyosarcoma in patients treated with UPA: clinical data are reported. The aim of this case report is to increase clinicians' awareness that, although rare, leiomyosarcoma can develop in a uterus with multiple myomas and no reliable diagnostic tools exist yet. Thus, a clinical and instrumental careful reevaluation and patient counseling should be a priority when planning to repeat UPA treatment cycles.